Skip to content
Open access

IGFBP2 attenuates high glucose-induced endothelial dysfunction through PI3K/Akt/eNOS pathway activation

Oct 2026 · Bioscience Reports · Vol 46 · 0 citations · 38 references
Medicine

Abstract

Abstract Endothelial dysfunction induced by hyperglycemia is a key event in diabetic vascular complications and is closely associated with impaired PI3K/Akt/endothelial nitric oxide synthase (eNOS) signaling. Insulin-like growth factor-binding protein 2 (IGFBP2) has been implicated in metabolic regulation and cell survival, but its role in high glucose (HG)-induced endothelial injury remains unclear. In the present study, human umbilical vein endothelial cells (HUVECs) were exposed to HG (33 mM) for 24 h and then treated with recombinant human IGFBP2 (rhIGFBP2, 200 ng/ml) for 60 min. HG reduced Akt/eNOS phosphorylation and nitric oxide (NO) production, increased the expression of ICAM-1, VCAM-1, and SELE, promoted interleukin-6, interleukin-8, monocyte chemoattractant protein-1 secretion, and enhanced apoptosis. rhIGFBP2 attenuated these HG-induced changes by restoring PI3K/Akt/eNOS signaling and NO production, reducing inflammatory activation, and decreasing apoptotic cell percentage. The effect of rhIGFBP2 on Akt/eNOS phosphorylation and NO production was broadly comparable to that of insulin under HG conditions. HG also increased p38 MAPK phosphorylation, whereas rhIGFBP2 showed only a nonsignificant decreasing trend. Importantly, PI3K inhibition with LY294002 abolished rhIGFBP2-induced Akt/eNOS activation, supporting the involvement of the PI3K/Akt/eNOS pathway. These findings suggest that IGFBP2 protects against HG-induced endothelial dysfunction mainly by activating PI3K/Akt/eNOS signaling and may represent a potential mediator of endothelial protection under diabetic conditions.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.